EcoDrugPlus

C-C Motif Chemokine Receptor 5

Ensembl ID : ENSSTOG00000001674
Gene Symbol: CCR5
3 Cross references
298 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSSTOG00000024611
Gene Symbol: CCR9
4 Cross references
262 Possible Orthologues:

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSSTOG00000003271
Gene Symbol: CXCL8
4 Cross references
181 Possible Orthologues:

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSSTOG00000013063
Gene Symbol: CXCR1
4 Cross references
158 Possible Orthologues:

C-X-C Motif Chemokine Receptor 2

Ensembl ID : ENSSTOG00000013059
Gene Symbol: CXCR2
3 Cross references
237 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSSTOG00000006334
Gene Symbol: CXCR4
4 Cross references
283 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSSTOG00000010841
Gene Symbol: DNMT1
3 Cross references
206 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSSTOG00000006028
Gene Symbol: TOP1
4 Cross references
270 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSSTOG00000004794
Gene Symbol: TOP2A
4 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSSTOG00000008012
Gene Symbol: TOP2B
3 Cross references
208 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSSTOG00000016266
Gene Symbol: EML4
4 Cross references
209 Possible Orthologues:

Eph Receptor A2

Ensembl ID : ENSSTOG00000003080
Gene Symbol: EPHA2
4 Cross references
124 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).